Systematic Review of Biological Modulation of Healing in Anterior Cruciate Ligament Reconstruction

Sai-Chuen Fu,† PhD, Yau-Chuk Cheuk,† MPhil, Shu-Hang Yung,† FRCS Ed (Orth), Christer Gustav Rolf,‡ PhD, and Kai-Ming Chan,‡§ MCh (Orth), FRCS

Investigation performed at the Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

Background: Whether biological modulation is effective to promote healing in anterior cruciate ligament (ACL) reconstruction remains unclear.

Purpose: To perform a systematic review of both clinical and experimental evidence of preclinical animal studies on biological modulation to promote healing in ACL reconstruction.

Study Design: Systematic review; Level of evidence, 2.

Methods: A systematic search was performed using the PubMed, Ovid, and Scopus search engines. Inclusion criteria were clinical and animal studies involving subjects with ACL injury with the use of biological modulation to promote healing outcomes. Methodological quality of clinical studies was evaluated using the Critical Appraisal Skill Programme (CASP) appraisal tool, and animal studies were evaluated by a scoring system based on a published checklist of good animal studies.

Results: Ten clinical studies and 50 animal studies were included. Twenty-five included studies were regarded as good quality, with a methodological score ≥5. These studies suggested that transforming growth factor–beta (TGF-β), mesenchymal stem cells, osteogenic factors, and modalities that reduce local inflammation may be beneficial to promote graft healing in ACL reconstruction.

Conclusion: This systematic review suggests that biological modulation is able to promote healing on top of surgical treatment for ACL injuries. This treatment strategy chiefly works through promotion of healing at the tunnel-graft interface, but the integrity of the intra-articular midsubstance of the graft would be another target for biological modulation.

Keywords: anterior cruciate ligament; growth factor; cell therapy; biological modulation

Currently, there are myriad studies investigating improvements in surgical methods for anterior cruciate ligament reconstruction (ACLR), for example, bone tunnel construction and placement, graft choices, graft preparation, and graft fixation.3,19,21 Yet, perfect surgical techniques still need an adequate biological healing response to yield good clinical outcomes. Reports have attributed poor graft healing as one of the causes leading to nontraumatic ACLR failure.5,15 Graft healing of ACLR involves slow biological processes,18 which are primarily attributed to graft remodeling such as intratunnel graft incorporation and intraarticular graft ligamentization.50 Previous approaches to enhance the healing at the graft-tunnel interface include the use of mesenchymal stem cells, growth factors, biomaterials, or biophysical intervention. Most of these preclinical animal studies still need further scrutiny to see if further clinical trials were worthwhile. An overall picture of the current development on biological modulation for ACLR would be obtained by performing a systematic review of both clinical and preclinical evidence. By critical appraisal on the study quality and significance of these studies, a better understanding on the effectiveness of biological modulation on ACLR can be attained. A summary of the...
proposed mechanisms of the treatment effect may also provide insights for further development of new approaches of biological modulation for ACLR.

The purposes of this study were (1) to perform a systematic review on the effectiveness of biological modulation to promote healing in ACLR, (2) to evaluate different biological modulations based on the proposed mechanisms, and (3) to evaluate the clinical significance of preclinical animal studies on biological modulation of ACLR.

METHODS

Study Selection

The inclusion criteria for studies in this systematic review consisted of the following:

- **Study types:** Clinical studies and animal studies. Studies included in searched reviews or systematic reviews were also tracked.
- **Study group:** Patients with ACL tears who received surgical treatment; animal models with ACL injuries.
- **Intervention type:** Drugs, growth factors, cells, interface biomaterials to promote graft incorporation, and biophysical interventions that stimulate healing.
- **Language:** No restriction.

The exclusion criteria consisted of the following:

- **Study types:** Studies of natural healing without intervention, in vitro studies, and studies without a control group.
- **Article type:** Articles other than original research articles.
- **Intervention types:** Interventions not related to biological modulation to promote healing, such as surgical treatments (direct sutures, fixation methods), artificial grafts or screws that do not aim at biological modulation, anesthetics, analgesics, and rehabilitation protocols.

Search Strategies

Systematic searches were carried out in January 2013 using PubMed, Ovid, and Scopus databases. The keywords in combination with search operators were as follows: (ACL OR anterior cruciate ligament) AND (growth factor OR stem cell OR drug OR biomaterial OR biophysical intervention). A postsearch filtering with keywords reconstruction, reconstructive, and healing in the titles was used to facilitate the identification of relevant studies. Studies with biological modulation on ACL lesion without reconstructive surgery were also identified by screening the titles. The search results from 3 different databases were merged, and...
duplicate studies were removed. Application of inclusion/exclusion criteria on the search results was started by screening the title and then the abstracts. The full text of the filtered articles was then obtained for data extraction, such as publication years, first author, type of modulation, animal model, sample size, follow-up time, key outcome measures, and major findings. A flowchart of the search results is shown in Figure 1. After the original search in January 2013, an updated search was conducted in January 2014 to cover publications from January 2013 to January 2014. The search criteria remained the same as the original search.

Assessment of Study Quality

Scientific evidence for effectiveness of biological modulation of healing of ACL injuries includes information from both clinical trials and preclinical animal studies. Clinical trials (level 1 or 2) are regarded as “high” evidence level, and the Critical Appraisal Skill Programme (CASP) appraisal form was used to evaluate the study quality. Animal studies are of lower evidence level, and they can be further stratified into 5 ranks based on outcome measures:

A: Quantitative outcome measures analogous to clinical outcome measures (eg, knee laxity, activity level, and gait)
B: Mechanical test of graft complex strength (ultimate load, linear stiffness) as quantitative outcome measures
C: Biochemical measurement as quantitative outcome measures
D: Semiquantitative imaging/histological assessment
E: Qualitative imaging/histological assessment

The quality of animal studies was assessed according to the criteria adapted from the checklist of Hooijmans et al. The quality of animal studies was assessed according to the criteria adapted from the checklist of Hooijmans et al.22 provided in Table 1.

### RESULTS

#### Search Results

In the original search, titles of 2424 studies were screened from the systematic searches; 2070 articles were filtered out with the absence of the keywords reconstruction, reconstructive, or healing. After applying exclusion criteria on the remaining 354 articles based on article type and study type, 254 articles were left. Fifty-nine studies included the use of biomaterials that did not involve biological modulation; 141 studies involved biological modulation that did not primarily promote healing (ie, pain relief, infection). Based on inclusion criteria, 54 studies were identified as clinical studies or animal studies that involved biological modulation to promote graft healing in ACLR. Screening the titles of the filtered 2070 articles further yielded 8 articles that might meet inclusion criteria. These studies used ACL surgery, bone-tendon healing, wound, injury, or ACL instead of healing/reconstruction in the titles. The abstracts of the 62 included articles were screened. Three studies were later excluded owing to duplication in Chinese and English literature with the same study design. Seven studies focused on biological modulation on intact ACLs and were thus excluded. One study was excluded because of a lack of a control group. One study was excluded since the full text was unavailable. Fifty studies were therefore included for data extraction and critical appraisal on study quality. In the

| TABLE 1 |
| Assessment Criteria of Methodological Quality of Animal Studies of ACLR$^a$ |

| Criteria | Score | Remarks |
|----------|-------|---------|
| 1. Unit of sample | Unilateral: 1 | Studies with bilateral operation may regard each limb as an independent sample and assign them to different treatment groups. Unless the sample unit was specified as number of animal instead of number of limbs, animal studies with unilateral operation as sample unit will be better. |
| Bilateral: 0 | | |
| 2. Standardization of surgical procedure | Yes: 1 | Standardization of surgical procedure includes the descriptions about graft harvest, approaching intra-articular region, drilling tunnels, graft tensioning, and fixation method. Studies with these descriptions would be regarded as standardized procedures as major surgical variables are controlled. |
| No: 0 | | |
| 3. Description of postoperative complications and follow-up | Yes: 1 | Records of postoperative complications such as broken sutures, wound infection, and early death are regarded to have better study quality. |
| No: 0 | | |
| 4. Report of failure mode in mechanical test | Yes: 1 | Since most ACLR animal studies used mechanical testing as the primary outcome, report of failure mode is important to reveal the quality and the implications of the mechanical tests. |
| No: 0 | | |
| 5. Variation (ratio of SD to mean) | <50%: 1 | For quantitative measure, large standard deviation may imply poor precision or large intra-group variations, which is regarded to have lower study quality. |
| >50%: 0 | | |
| 6. Statistical method | Appropriate: 1 | Questionable statistical analyses include the use of unpaired test for paired samples, parametric test for ordinal data with a few ranks, the use of unadjusted multiple comparisons instead of ANOVA or Kruskal-Wallis test. |
| Questionable: 0 | | |
| 7. Description of selection region of interest | Yes: 1 | For histology/imaging outcome measure, description of systematic/random sampling of region of interest is considered to provide better study quality. |
| No: 0 | | |
| 8. Semiquantitative scoring/image analysis | Yes: 1 | For histology/imaging outcome measure, implementation of scoring systems or image analysis protocol is considered to provide better study quality. |
| No: 0 | | |

$^a$ACLR, anterior cruciate ligament reconstruction; ANOVA, analysis of variance; SD, standard deviation.
| Year/Author | Biological Modulation | Type | Human/Animal | n | Surgery/Graft | Follow-up, Min-Max | Outcome Measures | Finding | Evidence Level | Quality Score |
|------------|-----------------------|------|--------------|---|--------------|-------------------|-----------------|--------|---------------|--------------|
| 2014/Silva et al<sup>49</sup> | Bone marrow concentrate | GF/drugs | Clinical | 43 | ACLR/HS, DB | 3 mo | Imaging | No difference | 2 | 4/10 |
| 2013/Zhang et al<sup>73</sup> | Autologous bone marrow | GF/drugs | Rabbit | 32 | ACLR/ST | 2 wk–12 wk | Histology, mech | Positive | B | 5/8 |
| 2013/Zhai et al<sup>40</sup> | PRP and demineralized bone protein | GF/drugs | Rabbit | 48 | ACLR/ST | 2 wk–4 wk–8 wk–12 wk | Histology, mech, imaging | Positive | B | 5/8 |
| 2013/Xie et al<sup>65</sup> | BMP2 injection | GF/drugs | Dog | 36 | ACLR/Flex | 2 wk–12 wk | Biochem | Positive | B | 3/8 |
| 2013/Weimin et al<sup>62</sup> | Calcium acid phosphate cement with bone xenograft/BMP composite | GF/drugs | Rabbit | 90 | ACLR/EXT | 6 wk–24 wk | Histology, mech, imaging | Positive | C | 1/8 |
| 2013/Oka et al<sup>63</sup> | Sinovastatin-conjugated gelatin hydrogel | GF/drugs | Rabbit | 42 | ACLR/HS | 2 wk–8 wk | Histology, mech, imaging | Positive | B | 6/8 |
| 2013/Mifune et al<sup>59</sup> | ACL-derived cell sheet | Cell | Rat | 27 | ACLR/Flex | 2 wk–8 wk | Histology, mech | Positive | B | 4/8 |
| 2013/Lui et al<sup>36</sup> | Alendronate (systemic) | GF/drugs | Rat | 84 | ACLR/HS | 2 wk–6 wk | Histology, mech, imaging | Positive | B | 7/8 |
| 2013/Lui et al<sup>35</sup> | Alendronate (local) | GF/drugs | Rat | 72 | ACLR/Flex | 2 wk–6 wk | Histology, mech, imaging | Positive | B | 7/8 |
| 2014/Hsu and Wang<sup>43</sup> | Demineralized bone matrix | Biomaterial | Rabbit | 10 | ACLR/EXT | 4 wk–12 wk | Histology, imaging | Positive | D | 5/8 |
| 2013/Cho et al<sup>8</sup> | Cationized gelatin and hyaluronic acid coating | GF/drugs | Purine | 6 | ACLR/PET | 3 mo | Histology, imaging | Positive | D | 5/8 |
| 2012/Shoji et al<sup>72</sup> | MicroRNA | GF/drugs | Rat | 55 | ACLT | 1 wk–4 wk | Histology, mech, biochem | Positive | B | 5/8 |
| 2012/Lee et al<sup>73</sup> | SIS/PRP | GF/drugs | Rabbit | 20 | ACLR/branched SIS | 1 wk–8 wk | Histology, mech, imaging | Negative | B | 5/8 |
| 2012/Kadonishi et al<sup>16</sup> | Enamel | Biomaterial | Rat | 30 | ACLR/Ten /Flex | 4 wk–12 wk | Histology, mech | Positive | B | 2/8 |
| 2012/Ediz et al<sup>14</sup> | Electrostimulation of BMSC-BMP2 | Cell | Clinical | 29 | ACLR/HS | 1 d–6 mo | Clinical, quest | Positive | 1 | 8/10 |
| 2012/Dong et al<sup>12</sup> | BMP2 injection | GF/drugs | Rabbit | 176 | ACLR/AT | 3 wk–24 wk | Histology, mech | Positive | B | 6/8 |
| 2012/Cho et al<sup>72</sup> | Periosteum progenitor cell sheet | Cell | Rabbit | 20 | ACLR/EXT | 8 wk | Histology, mech | Positive | B | 2/8 |
| 2012/Cho et al<sup>8</sup> | VEGF in hyaluronan | GF/drugs | Rabbit | 45 | ACLR/MBT | 2 wk–8 wk | Histology, mech | Positive | B | 4/8 |
| 2011/Zhang et al<sup>72</sup> | Bioactive scaffold | Biomaterial | Rabbit | 51 | ACLR/Flex | 12 wk | Histology, mech, imaging | No difference | B | 2/8 |
| 2011/Zhang et al<sup>71</sup> | Ginseng | GF/drugs | Rabbit | 20 | ACLR/EXT | 4 wk–8 wk | Histology | Positive | E | 3/8 |
| 2011/Wei et al<sup>60</sup> | TGF-β1/PRP transfected MSC | Cell | Rabbit | 176 | ACLR/AT | 3 wk–24 wk | Histology | Positive | E | 6/8 |
| 2011/Qin et al<sup>66</sup> | TGF-β (plasmid matrix BMP + materials | GF/drugs | Rabbit | 48 | ACLR/ST | 1 mo–6 mo | Histology | Positive | E | 2/8 |
| 2011/Pan et al<sup>65</sup> | Calcium acid phosphate | Biomaterial | Dog | 36 | ACLR/HS | 1 mo–6 mo | Histology, mech | Positive | B | 1/8 |
| 2011/Matsuzaki et al<sup>14</sup> | Calcium phosphate | Biomaterial | Goat | 18 | ACLR/HS, Flex | 1 y | Clinical, lax | Positive | A | 7/8 |
| 2011/Kondo et al<sup>30</sup> | TGF-β–treated synovial cells | Cell | Sheep | 52 | ACLR/ST | 1 wk–12 wk | Histology, mech | Positive | B | 5/8 |
| 2011/Hashimoto et al<sup>39</sup> | BMP2 injection | GF/drugs | Rabbit | 40 | ACLR/ST | 4 wk–8 wk | Histology, mech, imaging | Positive | B | 4/8 |
| 2011/Darabos et al<sup>39</sup> | Autologous conditioned serum | GF/drugs | Clinical | 62 | ACLR/HS, BTB | 10 d–12 mo | Imaging, quest, biochem | Positive | 1 | 8/10 |
| 2010/Wang et al<sup>29</sup> | BMP-transacted cells | Cell | Rabbit | 36 | ACLR/EXT | 1 wk–12 wk | Histology, mech, imaging | Positive | B | 6/8 |
| 2010/Vogrin et al<sup>58</sup> | PRP | GF/drugs | Clinical | 50 | ACLR/HS | 3 mo–6 mo | Lax | Positive | E | 6/10 |
| 2010/Shen et al<sup>31</sup> | Calcium phosphate ceramics | Biomaterial | Rabbit | 30 | ACLR/ST | 4 wk–12 wk | Histology | Positive | E | 2/8 |
| 2009/Wen et al<sup>40</sup> | Bone cement | Biomaterial | Rabbit | 28 | ACLR/Flex | 6 wk–12 wk | Histology, mech, imaging | Positive | B | 2/8 |
| 2009/Silva et al<sup>43</sup> | PRP | GF/drugs | Clinical | 40 | ACLR/HS, DI | 3 mo | Imaging | No difference | 2 | 1/10 |
| 2009/Papatheodorou et al<sup>46</sup> | LIPUS | Biophy | Rabbit | 52 | ACLR/EXT | 1 d–21 d | Biochem, histology | Positive | C | 3/8 |
| 2008/Zhang et al<sup>70</sup> | hBGF | GF/drugs | Dog | 14 | ACLR/EXT, ST | 1 wk–6 wk | Histology | Positive | E | 1/8 |
| 2008/Sasaki et al<sup>49</sup> | Granulocyte stimulating factor | GF/drugs | Dogs | 28 | ACLR/Flex | 2 wk–4 wk | Histology, mech, biochem, imaging | Positive | B | 2/8 |

(continued)
updated search carried out in January 2014, out of the 331 studies, 199 studies were excluded based on the absence of the keywords reconstruction, reconstructive, or healing, and 22 duplicate studies were removed. After screening the titles of the remaining 110 articles and applying the exclusion criteria based on article type and study type, only 10 studies were included for data extraction.

### Data Extraction

The study characteristics of both the original and updated search are provided in Table 2. Of the 60 included studies, 3 tested the effects of biophysical intervention; 11 tested the effects of cells alone or in combination with growth factors or scaffold, 37 evaluated growth factors or drugs with or without biomaterials, and 9 evaluated the biological effect of biomaterials. Ten clinical studies were included; 2 tested the effects of biophysical intervention and 8 investigated growth factors or drugs. More than half of the animal studies (n = 31) utilized a rabbit model, 8 studies used dogs, 3 studies used sheep, 6 studies used rats, 1 study used a porcine, and 1 study used a goat model. Most included studies involved ACLR surgery, except 6 studies that used animal models of ACL partial lesion and 1 on overstretched ACL injury. Various types of grafts were used in the included studies. Both hamstring and bone-tendon-bone (BTB) grafts were used in the clinical studies. In rabbit models, semitendinosus and extensor grafts were preferred but

### Table 2 (continued)

| Year/Author | Biological Modulation | Type | Human/Animal | n | Follow-up, Min-Max | Outcome Measures | Finding | Evidence Level | Quality Score |
|-------------|-----------------------|------|--------------|---|-------------------|-----------------|---------|----------------|---------------|
| 2008/Orrego et al<sup>a</sup> | Platelet concentrate + bone plug | GF/drugs | Clinical | 108 | ACLR/ST | Imaging | No difference | 2 | 4/10 |
| 2008/Fanton et al<sup>b</sup> | Ketoprofen, amitriptyline, and oxymetazoline | GF/drugs | Clinical | 35 | ACLR/Allo | 1 d–30 d | Clinical, pain | Positive | 1 | 6/10 |
| 2008/Benazzo et al<sup>c</sup> | Pemphigus | Biophy | Clinical | 84 | ACLR/HS | 30 d–180 d | Quest | Positive | 1 | 4/10 |
| 2008/Babhi et al<sup>d</sup> | MSC | Cell | Immature rabbit | 15 | ACLR/EXT | 3 wk–20 wk | Imaging, histology | Positive | D | 5/8 |
| 2007/Soon et al<sup>e</sup> | MSC | Cell | Rabbit | 36 | ACLR/AT | 2 wk–8 wk | Histology, mech | Positive | B | 3/8 |
| 2007/Li et al<sup>f</sup> | MSC or PDGF-BB–transfected MSC | Cell | Rabbit | 36 | ACLR/AT | 3 wk–12 wk | Histology | Positive | E | 1/8 |
| 2007/Kanaya et al<sup>g</sup> | MSC | Cell | Rat | 98 | ACLR | 1 wk–4 wk | Histology, mech | Positive | B | 5/8 |
| 2007/Huangfu and M. Z. | TCP | Biomaterial | Dog | 48 | ACLR/Flex | 2 wk–12 wk | Histology, mech | Positive | B | 3/8 |
| 2007/Huang et al<sup>h</sup> | Hyaluronic acid | GF/drugs | Clinical | 120 | ACLR/BTB | 4 wk–16 wk | Clinical, quest | Positive | 1 | 4/10 |
| 2006/Yoshikawa et al<sup>i</sup> | VEGF | GF/drugs | Sheep | 18 | ACLR/ST | 12 wk | Histology, mech, lax | Negative | B | 6/8 |
| 2006/Dynibr et al<sup>j</sup> | Osteoprotegerin | GF/drugs | Rabbit | 15 | ACLR/ST | 3 wk | Histology, imaging | Positive | D | 6/8 |
| 2005/Yamazaki et al<sup>k</sup> | TGF(b) | GF/drugs | Dog | 21 | ACLR/Flex | 3 wk | Histology, mech | Positive | B | 8/8 |
| 2005/Ventura et al<sup>l</sup> | Growth factor | GF/drugs | Clinical | 20 | ACLR/HS | 6 mo | Imaging, quest, biochem | Positive | 1 | 1/10 |
| 2005/Kondo et al<sup>m</sup> | TGF(b), PDGF-BB | GF/drugs | Rabbit | 36 | Overstretch injury | 12 wk | Histology, mech, lax | Positive | A | 5/8 |
| 2005/Demirag et al<sup>n</sup> | Blockade of MMP-2 macroglobulin | GF/drugs | Rabbit | 28 | ACLR/ST | 2 wk–5 wk | Histost, mech, biochem | Positive | B | 3/8 |
| 2004/Yasuda et al<sup)o</sup> | TGF(b) + EGF | GF/drugs | Dog | 25 | ACLR/BTB | 12 wk | Histology, mech | Positive | A | 5/8 |
| 2004/Weiler et al<sup>p</sup> | PDGF-BB | GF/drugs | Sheep | 48 | ACLR/Flex | 3 wk–24 wk | Histology | No difference | A | 7/8 |
| 2004/Tien et al<sup>q</sup> | Calcium phosphate cement | Biomaterial | Rabbit | 22 | ACLR/ST | 1 wk–24 wk | Histology, mech | Negative | B | 4/8 |
| 2004/Lim et al<sup>r</sup> | MSC | Cell | Rabbit | 48 | ACLR/ST | 2 wk–8 wk | Histology, mech | Positive | B | 4/8 |
| 2004/Demirag et al<sup>s</sup> | β2 macroglobulin | GF/drugs | Rabbit | 20 | ACLT | 10 d | Histology, mech | Positive | E | 3/8 |
| 2001/Anderson et al<sup>t</sup> | Bone growth factor | GF/drugs | Rabbit | 70 | ACLR/ST | 2 wk–8 wk | Histology, mech | Positive | B | 4/8 |
| 1997/Koyashi et al<sup>u</sup> | bFGF | GF/drugs | Dog | 34 | ACLT | 1 wk–24 wk | Histology, mech | Positive | E | 1/8 |
| 1997/Kikuchi et al<sup>v</sup> | Hyaluronan | GF/drugs | Rabbit | 36 | ACLT | 2 wk–6 wk | Histology | Positive | E | 4/8 |
| 1990/Wiig et al<sup>w</sup> | Hyaluronic acid | GF/drugs | Rabbit | 21 | ACLT | 4 wk–12 wk | Histology | Positive | E | 1/8 |

<sup>a</sup>ACL, anterior cruciate ligament; ACLR, ACL reconstruction; ACLT, ACL transaction; Allo, allograft; AT, Achilles tendon; bFGF, basic fibroblast growth factor; Biochem, biochemical assay; Biophy, biophysical intervention; BMP, bone morphogenetic protein; BMP2, bone morphogenetic protein–2; BMSC, bone marrow–derived mesenchymal stem cell; BTB, bone-tendon-bone; DB, double-bundle; EGF, epidermal growth factor; EXT, extensor; Flex, flexor tendon; GAS, gastrocnemius; GF, growth factor; HS, hamstring tendon; Lux, laxity test; LIPUS, low-intensity pulsed ultrasound; Mech, mechanical test; MMP, matrix metalloproteinase; MSC, mesenchymal stem cell; PDGF-BB, platelet-derived growth factor–BB; PEMF, pulsed electromagnetic fields; PET, polyethylene terephthalate artificial ligament; PRP, platelet-rich plasma; Quest, questionnaire; SIS, small intestine submucosa; ST, semitendinosus; TCP, tricalcium phosphate; TGF(b), transforming growth factor–beta; VEGF, vascular endothelial growth factor.

The Orthopaedic Journal of Sports Medicine Biological Modulation for ACL Reconstruction 5
other graft types were also used. There were no preferred graft types in studies on dogs, and the graft preference was not clear in sheep, goat, or rat models because of the small sample sizes. Two animal studies investigated the effect of biological modulation on allografts, and 2 animal studies evaluated artificial grafts. The maximum follow-up time was 12 months in both clinical and animal studies. Most studies reported positive effects with the biological modulation under investigation; 6 studies reported no difference, and only 2 animal studies reported negative effects with platelet-rich plasma (PRP) and vascular endothelial growth factor (VEGF), respectively. Among the 6 reports of no difference, 3 evaluated platelet factors, 2 biomaterials, and 1 bone marrow concentrate.

Methodological Quality Assessment

The results of the methodological quality assessment are shown in the last 2 columns of Table 2. For clinical studies, 3 were rated as evidence level 2, and the rest were rated as level 1. Four clinical studies scored 6 or higher out of 10 in CASP, while 6 clinical studies scored less than 5 and were considered low quality. For animal studies, 4 studies were ranked “A” regarding clinically relevant quantitative outcome measures, and the methodological scores were all higher than 5 out of 8. Thirty-one animal studies were ranked “B” with the use of mechanical test outcome measures. The methodological score of these studies ranged from 1 to 8, with only 13 studies scoring 5 or higher. Two rank-“C” studies were included with quantitative biochemical outcome measure, and the study quality was low (1 and 3, respectively). Four rank-“D” studies with semiquantitative outcome measures and their methodological score were fair to satisfactory (4 in 1 study, 5 in 2 studies, 6 in 1 study). However, none of the rank-“E” studies scored higher than 4, and all of them were considered low-quality studies. In summary, only 25 included studies were appraised with satisfactory study quality, and further metasynthesis was performed on these studies. Good interobserver reliability was obtained between assessors (S.C.F. and Y.C.C.; intra-class correlation coefficient average measures, 0.848), and consensus on scoring was reached by discussion.

Metasynthesis

In the 25 good-quality studies (methodological score ≥5), 1 involved the use of biophysical intervention, 2 used biomaterials, 5 involved the use of cells, and tested the effects of growth factors or drugs. Four animal studies found positive results with the use of transforming growth factor–beta (TGF-β) in different combinations to promote bone-tendon junction healing. Three animal studies tested the effects of VEGF-mediated angiogenesis, but the results were inconsistent. Two animal studies tested the effects of platelet-derived growth factor–BB (PDGF-BB) and reported positive findings. The use of bone morphogenetic protein (BMP)-transfected cells, osteoprotegrin, calcium phosphate, and demineralized bone matrix primarily targeted osteogenesis inside the bone tunnel, and positive findings were reported. The use of bisphosphonate-targeted inhibition of bone resorption yielded similar effects. One clinical study observed beneficial effects of PRP, but in another animal study, PRP exerted negative effects in the context of small intestine submucosa (SIS) artificial graft. Two animal studies revealed the beneficial effects of supplementation of mesenchymal stem cells (MSCs) alone. Three clinical studies reported improvements in knee functions and pain score with control of postsurgical local inflammation and swelling by electrostimulation, intra-articular injection of autologous serum for interleukin–1 beta (IL-1β) antagonization, or drug formulation in arthroscopic irrigation saline for allograft ACLR, whereas 1 animal study reported alleviating inflammation by cationized gelatin and hyaluronic acid coating on artificial graft, which could improve healing at the bone-graft interface.

With respect to outcome measures, 2 clinical studies achieved improved pain and knee functions, while another reported significant improvements in imaging and biochemical outcome measures. All good-quality animal studies used mechanical tests of pull-out strength of the graft complex as the key outcome except 4 studies, which only reported histological findings alone or together with imaging findings. One study in a sheep model evaluated healing outcomes with in situ force and knee laxity. All good-quality studies involved ACLR surgery except 3, which investigated ACL partial lesions in rats or focused on overstretched ACL injury in rabbits.

DISCUSSION

Proposed Mechanism

This systematic review shows that there is good evidence for biological modulation to promote healing in ACLR. The proposed mechanisms for the biological modulation fell into 5 categories: (1) bone-tendon healing at the graft-tunnel interface, (2) angiogenesis, (3) osteogenesis, (4) cell supplementation for general healing capacity, and (5) reduction of local inflammation.

Although the intra-articular midsubstance would be the weakest link of the graft-complex in ACLR, tendon-bone healing at tunnel interface was the target of most biological modulation. Notably, the roles of TGF-β on bone-tendon junction healing have been well demonstrated in other animal models, thus it is not surprising to see the effectiveness of TGF-β in promoting graft incorporation in ACLR. Since tunnel widening is an adverse healing outcome of ACLR, strategies that promote osteogenesis or reduce bone resorption also worked to improve the pull-out strength of the graft complex. Studies of cell supplementation also targeted the graft-tunnel interface. However, overall improvement was limited by graft deterioration at the intra-articular space. Strategies to reduce graft deterioration by reducing local inflammation or direct modulation on degradative enzymes may be complementary to
treatment that targeted tunnel interface healing. From the search results, only 1 included study used nonsteroidal anti-inflammatory drugs (NSAIDs) as one of the components in the treatment formula. Based on the current search results, it is difficult to conclude that NSAIDs should be used freely for pain control without affecting knee function. However, as inflammation is necessary for the early healing phase and excessive inflammation may hamper the healing outcome, it is critical to control the extent of inflammation. The use of NSAIDs to control excessive inflammation without affecting knee function would be a primary concern for clinicians. With respect to angiogenesis, the current evidence is not consistent, especially with respect to the effects of VEGF. Revascularization would be essential to graft survival, but vascular invasion into the graft may also cause graft weakening. In summary, the current evidence suggests that biological modulation benefited healing by promoting graft incorporation at the tunnel interface, and further works on reducing graft deterioration may be worthwhile.

Practical Significance

For all included animal studies, the pull-out strength of the graft complex in the untreated control group was around 10% of the ultimate strength of the intact ACL, and the improvement by biological modulation was around 22% at maximum. As the clinical graft failure rate for ACLR is around 8%, the practical significance of the improvement in pull-out strength is questionable. However, as ACL in situ force during walking/descending stairs approached 7.8%/20% of ACL ultimate load, the improvement may help a little to avoid rerupture during daily activities. Knee laxity measurement and knee function scores are routinely used in clinical settings. However, only a few animal studies measured knee laxity and knee functions. Clinical studies showed that treatment delivered intraoperatively or during early healing phases could improve knee function at later time points, indicating the potential of biological modulation of postoperative local inflammation for long-term functional recovery. From the results of the systematic search, we found the maximum follow-up time point is 12 months. Since graft healing after ACL reconstruction is a lengthy process, a longer follow-up of 2 years would better reveal the effectiveness of the treatment modalities.

Representativeness of Animal Models

Currently available clinical studies on biological modulation of ACLR only tested the effects of biophysical intervention, autologous growth factor mixtures, or marketed drugs. The effectiveness of growth factors, cells, and biomaterials was only shown in animal studies, and their validity depends on the representativeness of the animal models. It has been demonstrated that there are significant anatomical differences in ACLs between human and experimental animals, and the obvious variations in gait and posture defined the differences of the biomechanical properties. However, there is also evidence about the homology of regenerative responses in mammals and the similar patterns of innervation found in knee joint ligaments. Thus, animal studies of ACLR may still convey useful information for further development but extrapolation of preclinical data may need further scrutiny, say, taking a plurispecies approach to confirm the findings.

Factors That Modify Treatment Effects

It is well accepted that evaluation of treatment effects should consider time of application and time of evaluation, dose response, and other ancillary conditions such as rehabilitation and activity levels. As most included animal studies did not include investigation of dose response, the observed treatment effects could not be further confirmed. Moreover, all studies of biological modulation of ACLR used intraoperative delivery except those with biophysical intervention. This is likely because of the practical difficulties of noninvasive delivery of the biological agents during the lengthy postoperative recovery phase. As graft healing in ACLR involves different stages such as inflammation, cell recruitment, revascularization, matrix remodeling for graft incorporation, and ligamentization, there is no doubt that different types of biological augmentation may be needed at different healing stages. Therefore, it is not surprising that positive treatment effects were only observed at early time points but not at later time points as the intraoperative treatment effects would have been faded.

Analysis of Reporting Biases

This systematic review may be subject to publication bias as most of the included studies reported improvement (52 positive findings, 6 no difference, and 2 negative findings). Only 3 studies with positive results received commercial sponsorship, and their findings did not stand out from similar studies. We are certain that there are unpublished studies on biological modulation in ACLR, as shown in the conference abstracts at the Annual Meeting of the Orthopaedic Research Society. Besides, studies in gray literature are difficult to access using the current search strategy. To our knowledge, there are relevant studies published in new journals that are not included in the 3 search databases. Because we identified good-quality studies with an arbitrary cutoff score (≥5), it is likely that we may have missed some meaningful findings during the integration of clinical/experimental evidence. If we lowered the cutoff scores to 4, 12 studies would be further included. These studies revealed similar findings according to the mechanisms to promote healing. However, 2 studies reported the positive effects of hyaluronan with repeated intra-articular injection, which may represent a different mechanism for biological modulation of ACLR.

Further Steps to Modify the Current Clinical Practice

Before implementing any biological interventions, it is important to have evidence of their effectiveness for ACLR. Further research is required to determine the necessity and
timning of the interventions. From the clinical studies with reasonably good study quality (score 6-8 out of 10 in CASP), there is evidence that short-term clinical outcomes after ACLR were improved by preparations of growth factors,8,58 drugs,14 or electrostimulation.14 Most of these interventions improved outcomes related to postsurgical pain response, except 1 study with platelet gel that showed improvement in anterior-posterior knee laxity. These studies suggest that intra-operative interventions targeted to reduce inflammation or promote graft healing are beneficial for recovery after ACLR. Moreover, many preclinical experimental evidences suggested that healing outcome could be further improved with biological modulation. Thus, translational research to bring preclinical findings into good-quality clinical trials is essential for the use of effective biological modulation to improve healing outcomes in a clinical setting. The major trend in ACLR is modification of surgical procedures such as the use of different types of tendon grafts and fixation methods.3,19,21 Although this review showed great potential, biological modulations are still in the exploratory stage. More evidence from both preclinical and clinical studies is required for implementation in clinical practice.

REFERENCES

1. Anderson K, Seneviratne AM, Izawa K, Atkinson BL, Potter HG, Rodeo SA. Augmentation of tendon healing in an intrarticular bone tunnel with use of a bone growth factor. Am J Sports Med. 2001;29: 689-698.

2. Babb JR, Ahn JL, Azam NM, Canale ST, Beaty JH. Transphyseal anterior cruciate ligament reconstruction using mesenchymal stem cells. Am J Sports Med. 2008;36:1164-1170.

3. Baer GS, Harner CD. Clinical outcomes of allograft versus autograft in anterior cruciate ligament reconstruction. Clin Sports Med. 2007;26: 661-681.

4. Benazzo F, Zanon G, Pedrizzini L, et al. Effects of biophysical stimulation in patients undergoing arthroscopic reconstruction of anterior cruciate ligament: prospective, randomized and double blind study. Knee Surg Sports Traumatol Arthrosc. 2008;16:595-601.

5. Carson EW, Anisko EM, Restrepo C, Panariello RA, O’Brien SJ, Warren RF. Revision anterior cruciate ligament reconstruction: etiology of failures and clinical results. J Knee Surg. 2004;17:127-132.

6. Chen J, Yang L, Guo L, Duan X. Sodium hyaluronate as a drug-release system for VEGF 165 improves graft revascularization in anterior cruciate ligament reconstruction in a rabbit model. Exp Ther Med. 2012;4:430-434.

7. Chen LY, Whu SW, Chen CH, et al. Single-layer periosseum progenitor cell sheet significantly promotes tendon-bone healing in comparison with acellular collagen sheet in anterior cruciate ligament reconstruction. Formosan J Musculoskeletal Dis. 2012;3:1-8.

8. Cho S, Li H, Chen C, Jiang J, Tao H, Chen S. Cationised gelatin and hyaluronic acid coating enhances polyethylene terephthalate artificial ligament graft osseointegration in porcine bone tunnels. Int Orthop. 2015;37:507-513.

9. Darabos N, Haspi M, Moser C, Darabos A, Bartolek D, Groenemeyer D. Intra-articular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2011;19(suppl 1):S36-S46.

10. Demirag B, Sarisozen B, Durak K, Bilgen OF, Ozturk C. The effect of α-2 macroglobulin on the healing of ruptured anterior cruciate ligament in rabbits. Connect Tissue Res. 2004;45:23-27.

11. Demirag B, Sarisozen B, Ozer O, Kaplan T, Ozturk C. Enhancement of tendon-bone healing of anterior cruciate ligament grafts by blockage of matrix metalloproteinases. J Bone Joint Surg Am. 2005;87:2401-2410.

12. Dong Y, Zhang Q, Li Y, Jiang J, Chen S. Enhancement of tendon-bone healing for anterior cruciate ligament (ACL) reconstruction using bone marrow-derived mesenchymal stem cells infected with BMP-2. Int J Mol Sci. 2012;13:3605-3620.

13. Dynybl C, Kawamura S, Kim HJ, Ying L, Perka C, Rodeo SA. The effect of osteoprotegerin on tendon-bone healing after reconstruction of the anterior cruciate ligament: a histomorphological and radiographical study in the rabbit [in German]. Z Orthop Ihre Grenzgeb. 2006; 144:179-186.

14. Ediz L, Ceylan MF, Turktas U, Yanmis I, Hiz O. A randomized controlled trial of electrostimulation effects on effusion, swelling and pain recovery after anterior cruciate ligament reconstruction: a pilot study. Clin Rehabil. 2012;26:413-422.

15. Ekdamh M, Wang JH, Ronga M, Fu FH. Graft healing in anterior cruciate ligament reconstruction. Knee Surg Sports Traumatol Arthrosc. 2008;16:935-947.

16. Fenton GS, Dillingham MF, Wall MS, et al. Novel drug product to improve joint motion and function and reduce pain after arthroscopic anterior cruciate ligament reconstruction. Arthroscopy. 2008;24: 625-636.

17. Fu SC, Cheng WH, Cheuk YC, et al. Development of vitamin C irrigation saline to promote graft healing in anterior cruciate ligament reconstruction. J Orthop Trans. 2013;1:67-77.

18. Kulotta LV, Rodeo SA. Biology of autograft and allograft healing in anterior cruciate ligament reconstruction. Clin Sports Med. 2007; 26:509-524.

19. Hapa O, Barber FA. ACL fixation devices. Sports Med Arthosc. 2009; 17:217-223.

20. Hashimoto Y, Naka Y, Fukunaka K, Nakamura H, Takaoka K. ACL reconstruction using bone-tendon-bone graft engineered from the semitendinosus tendon by injection of recombinant BMP-2 in a rabbit model. J Orthop Res. 2011;29:1923-1930.

21. Herrington L, Wrapson C, Matthews M, Matthews H. Anterior cruciate ligament reconstruction, hamstring versus bone-patella tendon-bone grafts: a systematic literature review of outcome from surgery. Knee. 2005;12:41-50.

22. Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim. 2010;38:167-182.

23. Hsu SL, Wang CJ. The use of demineralized bone matrix for anterior cruciate ligament reconstruction: a radiographic, histologic, and immunohistochemical study in rabbits. J Surg Res. 2014;187: 219-224.

24. Huang MH, Yang RC, Chou PH. Preliminary effects of hyaluronic acid on early rehabilitation of patients with isolated anterior cruciate ligament reconstruction. Clin J Sport Med. 2007;17:242-250.

25. Huangfu X, Zhao J. Tendon-bone healing enhancement using injectable tricalcium phosphate in a dog anterior cruciate ligament reconstruction model. Arthroscopy. 2007;23:455-462.

26. Kadonishi Y, Deie M, Takata T, Ochi M. Acceleration of tendon-bone healing in anterior cruciate ligament reconstruction using an enamel matrix derivative in a rat model. J Bone Joint Surg Br. 2012;94: 205-209.

27. Kanaya A, Deie M, Adachi N, Nishimori M, Yanada S, Ochi M. Intra-articular injection of mesenchymal stromal cells in partially torn anterior cruciate ligaments in a rat model. Arthroscopy. 2007;23:610-617.

28. Kikuchi T, Fukui N, Sakuta T, Yamaguchi T, Sakai H, Oda H. Effect of hyaluronan on the healing of partially ruptured anterior cruciate ligament of rabbits. J Orthop Sci. 1997;2:31-39.

29. Kobayashi D, Kurosaka M, Yoshiha S, Mizuno K. Effect of basic fibroblast growth factor on the healing of ruptured anterior cruciate ligament. Connect Tissue Res. 2004;45:189-194.

30. Kondo E, Yasuda K, Katsura T, Hayashi R, Azuma C, Tohyama H. Local administration of autologous synovium-derived cells improve...
the structural properties of anterior cruciate ligament autograft reconstruction in sheep. Am J Sports Med. 2011;39:999-1007.

31. Kondo E, Yasuda K, Yamanaka M, Minami A, Toyohama H. Effects of administration of exogenous growth factors on biomechanical properties of the elongation-type anterior cruciate ligament injury with partial laceration. Am J Sports Med. 2005;33:188-196.

32. Lee AJ, Chung WH, Kim DH, et al. Anterior cruciate ligament reconstruction in a rabbit model using canine small intestinal submucosa and autologous platelet-rich plasma. J Surg Res. 2012;178:206-215.

33. Li F, Jia H, Yu C. ACL reconstruction in a rabbit model using irradiated Achilles allograft seeded with mesenchymal stem cells or PDGF-B gene-transfected mesenchymal stem cells. Knee Surg Sports Traumatol Arthrosc. 2007;15:1219-1227.

34. Lim JK, Hui J, Li L, Thambyah A, Goh J, Lee EH. Enhancement of tendon graft osteointegration using mesenchymal stem cells in a rabbit model of anterior cruciate ligament reconstruction. Arthroscopy. 2004;20:899-910.

35. Lui PP, Lee YW, Mok TY, Cheuk YC. Local administration of alendronate reduced peri-tunnel bone loss and promoted graft-bone tunnel healing with minimal systemic effect on bone in contralateral knee. J Orthop Res. 2013;31:1897-1906.

36. Lui PP, Lee YW, Mok TY, Cheuk YC, Chan KM. Alendronate reduced peri-tunnel bone loss and enhanced tendon graft to bone tunnel healing in anterior cruciate ligament reconstruction. Eur Cell Mater. 2013;25:78-96.

37. Manning CN, Kim HM, Sakiyama-Elbert S, Galatz LM, Havioglou N, Thomopoulos S. Sustained delivery of transforming growth factor beta three enhances tendon-to-bone healing in a rat model. J Orthop Res. 2011;29:1099-1105.

38. McDougall JJ, Bray RC, Sharkey KA. Morphological and immuno-histochemical examination of nerves in normal and injured collateral ligaments of rat, rabbit, and human knee joints. Anat Rec. 1997;248:29-39.

39. Mifune Y, Matsumoto T, Takayama K, et al. Tendon graft revitalization using adult anterior cruciate ligament (ACL)-derived CD34+ cell sheets for ACL reconstruction. Biomaterials. 2013;34:5476-5487.

40. Morrison JB. The mechanics of the knee joint in relation to normal walking. J Biomech. 1970;3:51-61.

41. Mutsuzaki H, Sakane M, Fujie H, Hattori S, Kobayashi H, Ochiai N. Effect of calcium phosphate–hybridized tendon graft on biomechanical behavior in anterior cruciate ligament reconstruction in a goat model: a novel technique for improving tendon-bone healing. Am J Sports Med. 2011;39:1099-1106.

42. Ni F, Huangfu XQ, Zhao JZ, Sha L, Xie GM. Effect of calcium acid phosphate and calcium sulfate on tendon-bone healing. J Clin Rehabil Tissue Eng Res. 2011;15:3815-3821.

43. Oka S, Matsumoto T, Kubo S, et al. Local administration of low-dose simvastatin-conjugated gelatin hydrogel for tendon-bone healing in anterior cruciate ligament reconstruction. Tissue Eng Part A. 2013;19:1233-1243.

44. Orrego M, Larrain C, Rosales J, et al. Effects of platelet concentrate and a bone plug on the healing of hamstring tendons in a bone tunnel. Arthroscopy. 2008;24:1373-1380.

45. Pan W, Wei Y, Zhou L, Li D. Comparative in vivo study of injectable biomaterials combined with BMP for enhancing tendon graft osteointegration for anterior cruciate ligament reconstruction. J Orthop Res. 2011;29:1015-1021.

46. Papatheodorou LK, Malizos KN, Poultisides LA, et al. Effect of transosseous application of low-intensity ultrasound at the tendon graft-bone interface healing: gene expression and histological analysis in rabbits. Ultrasound Med Biol. 2009;35:S76-584.

47. Proffen BL, McElfresh M, Fleming BC, Murray MM. A comparative anatomical study of the human knee and six animal species. Knee. 2012;19:493-499.

48. Qin J, Hou ZQ, Wang XL, et al. Histological study of enhancing the healing of anterior cruciate ligament autogenous graft with gene activated matrix materials. J Clin Rehabil Tissue Eng Res. 2011;15:8778-8791.

49. Sasaki K, Kuroda R, Ishida K, et al. Enhancement of tendon-bone osteointegration of anterior cruciate ligament graft using granulocyte colony-stimulating factor. Am J Sports Med. 2008;36:1519-1527.

50. Scheffler SU, Unterhuaser FN, Weiler A. Graft remodeling and ligamentization after cruciate ligament reconstruction. Knee Surg Sports Traumatol Arthrosc. 2008;16:834-842.

51. Shen H, Qiao G, Cao H, Jiang Y. An histological study of the influence of osteoinductive calcium phosphate ceramics on tendon healing pattern in a bone tunnel with suspensory fixation. Int Orthop. 2010;34:917-924.

52. Shoji T, Nakasa T, Yamazaki K, et al. The effect of intra-articular injection of microRNA-210 on ligament healing in a rat model. Am J Sports Med. 2012;40:2470-2478.

53. Silva A, Sampaio R. Anatomic ACL reconstruction: does the platelet-rich plasma accelerate tendon healing? Knee Surg Sports Traumatol Arthrosc. 2009;17:676-682.

54. Silva A, Sampaio R, Fernandes R, Pinto E. Is there a role for adult noncultivated bone marrow stem cells in ACL reconstruction? Knee Surg Sports Traumatol Arthrosc. 2014;22:66-71.

55. Soon MY, Hassan A, Hui JH, Goh JC, Lee EH. An analysis of soft tissue allograft anterior cruciate ligament reconstruction in a rabbit model: a short-term study of the use of mesenchymal stem cells to enhance tendon osteointegration. Am J Sports Med. 2007;35:962-971.

56. Tien YC, Chih TT, Lin JH, Ju CP, Lin SD. Augmentation of tendon-bone healing by the use of calcium-phosphate cement. J Bone Joint Surg Br. 2004;86:1072-1076.

57. Ventura A, Terzaghi C, Borgo E, Verdoia C, Gallazzii M, Failoni S. Use of growth factors in ACL surgery: preliminary study. J Orthop Traumatol. 2005;6:76-79.

58. Vogrin M, Rupreht M, Cnjac A, Dinevski D, Krajncz Z, Recgnk C. The effect of platelet-derived growth factors on knee stability after anterior cruciate ligament reconstruction: a prospective randomized clinical study. Wien Klin Wochenschr. 2010;122(suppl 2):91-95.

59. Wang CJ, Weng LH, Hsu SL, et al. pCMV-BMP-2-transfected cell-mediated gene therapy in anterior cruciate ligament reconstruction in rabbits. Arthroscopy. 2010;26:968-976.

60. Wei X, Mao Z, Hou Y, et al. Local administration of TGFβ1-VEGF165 gene-transduced bone mesenchymal stem cells for Achilles allograft replacement of the anterior cruciate ligament in rabbits. Biochem Biophys Res Commun. 2011;406:204-210.

61. Weiler A, Förster C, Hunt P, et al. The influence of locally applied platelet-derived growth factor–BB on free tendon graft remodeling after anterior cruciate ligament reconstruction. Am J Sports Med. 2004;32:881-891.

62. Weimn P, Dan L, Yiyoung W, Yunhu H, Li Z. Tendon-to-bone healing using an injectable calcium phosphate cement combined with bone xenograft/BMP composite. Biomaterials. 2013;34:9926-9936.

63. Wen CY, Qin L, Lee KM, Chan KM. The use of brushes calcium phosphate cement for enhancement of bone-tendon integration in an anterior cruciate ligament reconstruction rabbit model. J Biomed Mater Res B Appl Biomater. 2009;89:466-474.

64. Wieg ME, Amiel D, Van de Berg J, Kitabayashi L, Harwood FL, Arfors KE. The early effect of high molecular weight hyaluronan (hyaluronic acid) on anterior cruciate ligament healing: an experimental study in rabbits. J Orthop Res. 1990;8:425-434.

65. Xie X, Wu H, Zhao S, Xie G, Huangfu X, Zhao J. The effect of platelet-rich plasma on patterns of gene expression in a dog model of anterior cruciate ligament reconstruction. J Surg Res. 2013;180:80-88.

66. Yamazaki S, Yasuda K, Tomita F, Toyohara H, Minami A. The effect of transforming growth factor–β1 on intraosseous healing of flexor tendon autograft replacement of anterior cruciate ligament in dogs. Arthroscopy. 2005;21:1034-1041.

67. Yasuda K, Tomita F, Yamazaki S, Minami A, Toyohama H. The effect of growth factors on biomechanical properties of the bone–patellar tendon–bone graft after anterior cruciate ligament reconstruction: a canine model study. Am J Sports Med. 2004;32:870-880.

68. Yoshikawa T, Toyohama K, Katsura T, et al. Effects of local administration of vascular endothelial growth factor on mechanical characteristics...
of the semitendinosus tendon graft after anterior cruciate ligament reconstruction in sheep. *Am J Sports Med.* 2006;34:1918-1925.

69. Zhai W, Lv C, Zheng Y, Gao Y, Ding Z, Chen Z. Weak link of tendon-bone healing and a control experiment to promote healing. *Arch Orthop Trauma Surg.* 2013;133:1533-1541.

70. Zhang CL, Xu H, Fan HB, Zheng JP, Chen RB. Angiogenic effect of basic fibroblast growth factor on anterior cruciate ligament reconstruction with freeze-dried tendon implants at early stage: a histological observation. *J Clin Rehabil Tissue Eng Res.* 2008;12:10425-10429.

71. Zhang L, Li ZY, Sun J, et al. Effect of Panax Notoginseng Saponins on autograft tendon healing in bone tunnel: interface histological characteristics. *China J Orthop Trauma.* 2011;24:132-136.

72. Zhang W, Pan W, Zhang M, Wei Y. In vivo evaluation of two types of bioactive scaffold used for tendon-bone interface healing in the reconstruction of anterior cruciate ligament. *Biotechnol Lett.* 2011;33:837-844.

73. Zhang YL, Li N, Song YX, Fang YQ, Zhang H, Zhang JY. Condensed autologous bone marrow transplantation facilitates the tendon-bone healing. *Chin J Tissue Eng Res.* 2013;17:223-227.